PriceTargets.com logo

Liquidia - LQDA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $13.60
  • Forecasted Upside: 96.82%
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$6.91 As of 03/31/2023 01:00 AM ET
▲ +0.17 (2.52%)

This chart shows the closing price for LQDA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Liquidia Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LQDA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LQDA

Analyst Price Target is $13.60
▲ +96.82% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Liquidia in the last 3 months. The average price target is $13.60, with a high forecast of $20.00 and a low forecast of $3.00. The average price target represents a 96.82% upside from the last price of $6.91.

This chart shows the closing price for LQDA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in Liquidia. This rating has held steady since May 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
10/8/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/6/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
4/6/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
7/5/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
10/3/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
1/1/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/2/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
4/1/2023

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/17/2023Needham & Company LLCBoost TargetBuy$16.00 ➝ $18.00Low
2/3/2023Needham & Company LLCReiterated RatingBuy$16.00Low
11/9/2022WedbushReiterated RatingUnderperform$3.00Low
9/19/2022WedbushReiterated RatingUnderperform$3.00Low
9/6/2022BTIG ResearchBoost Target$20.00Low
9/1/2022Needham & Company LLCBoost TargetBuy$12.00 ➝ $16.00Low
9/1/2022WedbushDowngradeNeutral ➝ Underperform$4.00 ➝ $3.00Low
7/22/2022LADENBURG THALM/SH SHInitiated CoverageBuy$15.00Low
7/20/2022BTIG ResearchBoost TargetBuy$14.00 ➝ $17.00Low
5/31/2022BTIG ResearchInitiated CoverageBuy$14.00Medium
5/26/2022Bank of AmericaInitiated CoverageBuy$12.00Medium
2/3/2022HC WainwrightBoost TargetBuy$6.00 ➝ $16.00High
1/10/2022Needham & Company LLCBoost TargetBuy$8.00 ➝ $12.00High
1/7/2022WedbushReiterated RatingHold$6.00Low
11/8/2021Needham & Company LLCBoost TargetPositive ➝ Buy$5.00 ➝ $8.00High
3/24/2021HC WainwrightReiterated RatingBuy$6.00High
3/23/2021Needham & Company LLCLower TargetBuy$6.00 ➝ $5.00Medium
12/4/2020HC WainwrightInitiated CoverageBuy$6.00High
11/30/2020WedbushReiterated RatingHold$4.00High
11/20/2020WedbushDowngradeOutperform ➝ Neutral$20.00 ➝ $4.00High
10/15/2020WedbushLower TargetOutperform$38.00 ➝ $20.00High
7/7/2020Needham & Company LLCReiterated RatingBuy$24.00Medium
7/7/2020WedbushReiterated RatingBuy$38.00Low
6/12/2020WedbushReiterated RatingBuy$41.00High
5/13/2020WedbushReiterated RatingBuy$41.00Medium
5/6/2020CowenReiterated RatingOutperform$40.00Medium
5/3/2020WedbushReiterated RatingBuy$41.00Low
4/8/2020WedbushBoost TargetOutperform$37.00 ➝ $41.00High
3/11/2020WedbushReiterated RatingBuy$37.00High
3/11/2020Needham & Company LLCReiterated RatingBuy$30.00High
1/27/2020WedbushReiterated RatingBuy$37.00Low
12/25/2019WedbushLower TargetOutperform$50.00 ➝ $37.00High
11/15/2019WedbushReiterated RatingBuy$50.00Low
6/28/2019WedbushReiterated RatingBuy$50.00High
5/2/2019WedbushReiterated RatingBuyHigh
4/8/2019WedbushReiterated RatingBuy$49.00Medium
3/26/2019WedbushReiterated RatingBuy$48.00 ➝ $49.00Low
3/12/2019WedbushBoost TargetOutperform$47.00 ➝ $48.00Low
1/16/2019WedbushReiterated RatingBuy$47.00High
11/28/2018WedbushBoost TargetOutperform$28.00 ➝ $47.00Low
11/8/2018Jefferies Financial GroupInitiated CoverageBuy$27.00Medium
11/1/2018WedbushBoost TargetOutperform ➝ Buy$26.00 ➝ $28.00High
10/31/2018Needham & Company LLCSet TargetBuy$32.00Medium
10/31/2018CowenSet TargetBuy$40.00High
9/4/2018WedbushInitiated CoverageOutperform ➝ Outperform$26.00Medium
8/20/2018CowenInitiated CoverageOutperform$40.00High
8/20/2018Jefferies Financial GroupInitiated CoverageBuy$22.00High
8/20/2018Needham & Company LLCInitiated CoverageBuy ➝ Buy$30.00High
(Data available from 4/1/2018 forward)

News Sentiment Rating

0.43 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 32 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
Mentions as of
9/3/2022
  • 7 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
10/3/2022
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/2/2022
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/2/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/1/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/31/2023
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/2/2023
  • 4 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/1/2023

Current Sentiment

  • 4 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Liquidia logo
Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. It engages in novel products development used in PRINT technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. The company was founded on June 28, 2020 and is headquartered in Morrisville, NC.
Read More

Today's Range

Now: $6.91
Low: $6.76
High: $7.00

50 Day Range

MA: $7.01
Low: $6.16
High: $7.91

52 Week Range

Now: $6.91
Low: $3.26
High: $8.79

Volume

768,080 shs

Average Volume

526,421 shs

Market Capitalization

$447.01 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.11

Frequently Asked Questions

What sell-side analysts currently cover shares of Liquidia?

The following Wall Street research analysts have issued reports on Liquidia in the last twelve months: Bank of America Co., BTIG Research, LADENBURG THALM/SH SH, Needham & Company LLC, and Wedbush.
View the latest analyst ratings for LQDA.

What is the current price target for Liquidia?

5 Wall Street analysts have set twelve-month price targets for Liquidia in the last year. Their average twelve-month price target is $13.60, suggesting a possible upside of 96.8%. BTIG Research has the highest price target set, predicting LQDA will reach $20.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $3.00 for Liquidia in the next year.
View the latest price targets for LQDA.

What is the current consensus analyst rating for Liquidia?

Liquidia currently has 1 sell rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LQDA will outperform the market and that investors should add to their positions of Liquidia.
View the latest ratings for LQDA.

What other companies compete with Liquidia?

Other companies that are similar to Liquidia include Apollo Endosurgery, OraSure Technologies, Anika Therapeutics, AngioDynamics and Sight Sciences. Learn More about companies similar to Liquidia.

How do I contact Liquidia's investor relations team?

Liquidia's physical mailing address is 419 DAVIS DRIVE SUITE 100, MORRISVILLE NC, 27560. The company's listed phone number is (919) 328-4400 and its investor relations email address is [email protected] The official website for Liquidia is www.liquidia.com. Learn More about contacing Liquidia investor relations.